Table 1.
Stimuli | A. In vivo (DTH, mm ± SE) |
B. In vitro (Proliferation, cpm ± SE) |
||
---|---|---|---|---|
Treatment | Against F105 | Against Cz | Upon F105 | Upon Cz |
nEmpty | 0.010 ± 0.004 | 0.041 ± 0.015 | 859 ± 292 | 775 ± 408.4 |
nGM-CSF | 0.023 ± 0.014 | 0.042 ± 0.014 | 321 ± 111 | 269 ± 64 |
nCz | 0.096 ± 0.019* | 0.102 ± 0.015* | 5304 ± 1419* | 5214 ± 1785* |
nCz+nGM−CSF | 0.122 ± 0.013** | 0.106 ± 0.020* | 10209 ± 3143* | 8570 ± 2201** |
C3H/HeN mice challenged with a sublethal dose of RA trypomastigotes were treated by intramuscular route with 2 doses of nCz, nGM-CSF or nCz+nGM−CSF. The results represent the media of 7 determinations ± standard error, and are representative of 3 independent experiments. *p << 0.05; **p < 0.01.